ReviewMicroorganisms2024
Topical Antibiotic Therapy in the Ocular Environment: The Benefits of Using Moxifloxacin Eyedrops.
Review in Microorganisms, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 16 citations in OpenAlex.
- Efficacy of intracameral moxifloxacin in prevention of postcataract surgery endophthalmitis: randomized control trial.Journal of cataract and refractive surgery · 2026Trial
- Beyond the Barrier: Overcoming Ocular Antimicrobial Resistance Through AI and Novel Therapeutics.International journal of molecular sciences · 2026Review
- Chloramphenicol Application Onto the Eyelid: Transfersomes for Enhanced Skin Delivery.AAPS PharmSciTech · 2026Article
- Article
- Therapeutic Potential of Desert Truffles in the Management of Eye Infections: Demystifying the Fact.Combinatorial chemistry & high throughput screening · 2026Review
- Suppressive effect of topical moxifloxacin on imiquimod-induced model of psoriasis in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Country-Specific Approaches to Preventing Infections in Cataract Surgery.Antibiotics (Basel, Switzerland) · 2025Article
- Mechanisms and Evolution of Antimicrobial Resistance in Ophthalmology: Surveillance, Clinical Implications, and Future Therapies.Antibiotics (Basel, Switzerland) · 2025Review
- Traceless solid-phase synthesis of thiazolo[4,5-RSC advances · 2025Article
- Clinical Benefits of Ibuprofen Arginine: A Narrative Review.Pain and therapy · 2025Review
- Assessment of drug utilization evaluation and post-dispensing knowledge of ophthalmic medications: an explanatory sequential mixed-methods study at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.BMC health services research · 2025Article
- Characterization of Conjunctival Microflora and Antibiotic Sensitivity Patterns in Patients Undergoing Cataract Surgery.Microorganisms · 2025Article
- Synthesis and antibacterial evaluation of quinoline-sulfonamide hybrid compounds: a promising strategy against bacterial resistance.RSC advances · 2025Article
- Conservative management of paediatric dacryocystitis: a collection of clinical experiences highlighting effectiveness and parental satisfaction.Drugs in context · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moxifloxacin is a fourth-generation fluoroquinolone antibiotic available for ophthalmic use. It inhibits two enzymes involved in bacterial DNA synthesis, covering Gram-positive and Gram-negative pathogens. This spectrum allows for the formulation of self-preserving bottle solutions, while its interesting pharmacological profile is distinguished by efficacy at low tissue concentrations and by an infrequent dose regimen due to its long duration on ocular tissues. This enhances patient compliance, promoting its use in children. The human eye hosts several microorganisms; this collection is called the ocular microbiota, which protects the ocular surface, assuring homeostasis. When choosing an antibiotic, it is appropriate to consider its influence on microbiota. A short dose regimen is preferred to minimize the impact of the drug. Moxifloxacin eyedrops represent an effective and safe tool to manage and prevent ocular infections. As healthcare providers face the complexity of the ocular microbiota and microbial resistance daily, the informed use of moxifloxacin is necessary to preserve its efficacy in the future. In this regard, it is well known that moxifloxacin has a lower capacity to induce resistance (an optimal WPC and MPC) compared to other quinolones, but much still needs to be explored regarding the impact that fluoroquinolones could have on the ocular microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.